Ann: GUIDANCE ON CLINICAL TRIAL UPDATES, page-22

I emailed them about the timing of recruitment opening etc a few weeks back but received no reply. I gather they don't want to tell us directly that the lengthy process (like the the first patient) is about to be duplicated.

Again.... if they sell off stock because of impatience then smart money will be there picking up cheap shares.

It's a bit hard to work out ATM but I'm thinking that the safety data from the first two cohorts may be available for a late breaker at the AASLD meeting in early November. That would be nice. We can only guess so far but it will easier to work out when patient number two is dosed.